Evidence map›Paper›PMID 21320889›Full record

ArticleThe Journal of physiology2011

Preferential skeletal muscle myosin loss in response to mechanical silencing in a novel rat intensive care unit model: underlying mechanisms.

Julien Ochala, Ann-Marie Gustafson, Monica Llano Diez, Guillaume Renaud, Meishan Li, Sudhakar Aare, Rizwan Qaisar, Varuna C Banduseela, Yvette Hedström, Xiaorui Tang and 6 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02773771 (Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit), which is not on this map. Cited by 78 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02773771 phase2 / phase3withdrawnnot on this mapstarted 2017, after this paper: background citation

Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit (STROMA-ICU)

TypeinterventionalSponsorMassachusetts General HospitalRan2017 to 2019Enrolled0ConditionsMuscle AtrophyArmsbeta-hydroxy-beta-methylbutyrate, Placebo, Vital HP®
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 3 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. 'Cells · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Muscle Disuse Atrophy.Advances in experimental medicine and biology · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Pathophysiology and management of critical illness polyneuropathy and myopathy.Journal of applied physiology (Bethesda, Md. : 1985) · 2021
    Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Julien OchalaDepartment of Neuroscience, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden.
Ann-Marie Gustafson
Monica Llano Diez
Guillaume Renaud
Meishan Li
Sudhakar Aare
Rizwan Qaisar
Varuna C Banduseela
Yvette Hedström
Xiaorui Tang
Barry Dworkin
G Charles Ford
K Sreekumaran Nair
Sue Perera
Mathias Gautel
Lars Larsson
Uppsala University · SEKing's College London · GBMayo Clinic · USPenn State Milton S. Hershey Medical Center · US

Funding

Medical Research Council G0600251
6 · The paper itself

Abstract

The muscle wasting and impaired muscle function in critically ill intensive care unit (ICU) patients delay recovery from the primary disease, and have debilitating consequences that can persist for years after hospital discharge. It is likely that, in addition to pernicious effects of the primary disease, the basic life support procedures of long-term ICU treatment contribute directly to the progressive impairment of muscle function. This study aims at improving our understanding of the mechanisms underlying muscle wasting in ICU patients by using a unique experimental rat ICU model where animals are mechanically ventilated, sedated and pharmacologically paralysed for duration varying between 6 h and 14 days. Results show that the ICU intervention induces a phenotype resembling the severe muscle wasting and paralysis associated with the acute quadriplegic myopathy (AQM) observed in ICU patients, i.e. a preferential loss of myosin, transcriptional down-regulation of myosin synthesis, muscle atrophy and a dramatic decrease in muscle fibre force generation capacity. Detailed analyses of protein degradation pathways show that the ubiquitin proteasome pathway is highly involved in this process. A sequential change in localisation of muscle-specific RING finger proteins 1/2 (MuRF1/2) observed during the experimental period is suggested to play an instrumental role in both transcriptional regulation and protein degradation. We propose that, for those critically ill patients who develop AQM, complete mechanical silencing, due to pharmacological paralysis or sedation, is a critical factor underlying the preferential loss of the molecular motor protein myosin that leads to impaired muscle function or persisting paralysis.

Indexed as

Critical CareAnalysis of VarianceAnimalsDisease Models, AnimalDown-RegulationFemaleImmobilizationMuscle ContractionMuscle ProteinsMuscle, SkeletalMuscle StrengthMuscular AtrophyNeuromuscular Blocking AgentsParalysisPhenotypeProteasome Endopeptidase ComplexMuscle ProteinsNeuromuscular Blocking AgentsProteasome Endopeptidase ComplexRNA, MessengerSkeletal Muscle MyosinsTrim63 protein, ratTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID21320889
PMCPMC3090600
OpenAlexW2158354899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.